Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Oil Down Over Large Build in U.S. Supplies, but Boosted by COVID-19 Vaccine News

Published 12/08/2020, 10:38 PM
Updated 12/08/2020, 10:43 PM
© Reuters.

By Gina Lee

Investing.com – Oil was down on Wednesday morning in Asia, with concerns mounting after a larger-than-expected build in U.S. crude oil supplies during the previous week. However, positive vaccines news fueled hopes of a recovery in fuel demand and capped the black liquid’s losses.

Brent oil futures fell 0.45% to $48.62 by 11:39 PM ET (3:39 AM GMT) and WTI futures were down 0.44% to $45.40. Both Brent and WTI futures stayed above the $40 mark.

Data from the American Petroleum Institute released on Tuesday showed a 1.141-million-barrel build in U.S. crude oil supplies for the week ending Dec. 4.

The build was much bigger than the 1.514-million-barrel draw in forecasts prepared by Investing.com, but was down from the previous week’s 4.146-million-barrel build.

Investors now await crude oil supply data from the U.S. Energy Information Administration, due later in the day.

“The recent rally looks to be overdone from a fundamental point of view, given rising oil output in Libya and the United States with weaker fuel demand across the globe,” Fujitomi Co. chief analyst Kazuhiko Saito told Reuters.

“But the bullish tone is likely to continue amid hopes the pandemic can be brought under control with vaccines next year,” Saito added.

On the vaccines front, the U.K. has already seen the first patients inoculated with BNT162b2, the COVID-19 vaccine co-developed by Pfizer (NYSE:PFE) and BioNTech SE (F:22UAy). The U.K.’s Medicines & Healthcare Products Regulatory Agency granted a temporary authorization for emergency use of the vaccine during the previous week.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The U.S. Food and Drug Administration (FDA) will convene to discuss BNT162b2 on Thursday. Should the FDA grant emergency use authorization during its meeting, distribution could begin within 24 hours, according to Health & Human Services Secretary Alex Azar. The FDA has already released documents that raised no new red flags over the safety or efficacy of the vaccine ahead of the meeting.

The news helped allay investor fears as a sharp uptick in COVID-19 cases saw California, Germany, South Korea and Hong Kong all announce tightened restrictive measures in recent days.

The number of global COVID-19 cases has now passed the 68.1 million mark, with the number of U.S. cases passing the 15.1 million mark, as of Dec. 9, according to Johns Hopkins University data.

Meanwhile, in a further sign of increasing confidence in fuel recovery driven by COVID-19 vaccines, hedge fund managers were substantial buyers of petroleum futures and options last week for the fourth consecutive week.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.